Please assess the completion status of the following clinical trial:

Trial Title: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria included, but were not limited to the following:~1. Male or female, 18 years or older;~2. Chronic Atopic Dermatitis (AD) for at least 3 years;~3. History of inadequate response to a stable (\>/= 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit.~Exclusion Criteria:~1. Prior treatment with REGN668;~2. Presence of certain laboratory abnormalities at the screening visit;~3. Treatment with an investigational drug within 8 weeks ;~4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;~5. Certain treatments and medical procedures, undertaken within a particular time-frame prior to the baseline visit, preclude eligibility for participation in the study;~6. Known history of human immunodeficiency virus (HIV) infection;~7. History of malignancy within 5 years before the baseline visit, with certain exceptions;~8. Planned surgical procedure during the length of the patient's participation in this study;~9. History of clinical parasite infection;~10. Any medical or psychiatric condition which in the opinion of the investigator or the sponsor's medical monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results;~11. Pregnant or breast-feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
- Dupilumab 300 mg (Type: EXPERIMENTAL): Dupilumab 300 mg once weekly for 12 weeks by SC injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).